Immunostimulatory composition
    3.
    发明授权
    Immunostimulatory composition 有权
    免疫刺激成分

    公开(公告)号:US06210662B1

    公开(公告)日:2001-04-03

    申请号:US09344195

    申请日:1999-06-24

    IPC分类号: A01N6300

    摘要: Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

    摘要翻译: 公开了用于在体外和体内诱导细胞毒性T细胞应答的治疗组合物和方法。 治疗组合物由抗原呈递细胞组成,其通过与通过将树突状细胞结合蛋白和多肽抗原连接在一起而构建的多肽复合体接触而活化。 还公开了用于产生多肽复合物的表达载体和系统。

    Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody
    8.
    发明授权
    Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody 有权
    HLA-DR特异性单克隆抗体对肿瘤细胞的选择性凋亡

    公开(公告)号:US06416958B2

    公开(公告)日:2002-07-09

    申请号:US09929209

    申请日:2001-08-13

    IPC分类号: G01N3353

    摘要: Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.

    摘要翻译: 公开了抗人类主要组织相容性复合体(MHC)II类,可诱导HLA-DR阳性细胞凋亡的HLA-DR特异性单克隆抗体。 抗体用于通过HLA-DR的交联来特异性地消除HLA-DR抗原阳性肿瘤细胞。 还公开了使用这种抗体治疗癌症的方法和含有它们的组合物。